Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Company Performance - Invivyd, Inc. reported a quarterly loss of $0.40 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.37, and an improvement from a loss of $0.46 per share a year ago [1] - The company posted revenues of $2.26 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 53.85%, compared to zero revenues a year ago [2] - The stock has lost approximately 73.1% since the beginning of the year, contrasting with the S&P 500's gain of 13.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $43.01 million, and for the current fiscal year, it is -$0.60 on revenues of $173.95 million [7] - The estimate revisions trend for Invivyd, Inc. is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Invivyd belongs, is currently in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]